Related Experiment Video
Updated: Apr 25, 2026
Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques
Published on: June 1, 2016
Microglial Aβ receptors in Alzheimer's disease
1School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China, yuyang2011@sjtu.edu.cn.
Abstract:
Amyloid β (Aβ) plays a pivotal role in the progression of Alzheimer's disease (AD) through its neurotoxic and inflammatory effects. On one hand, Aβ binds to microglia and activates them to produce inflammatory mediators. On the other hand, Aβ is cleared by microglia through receptor-mediated phagocytosis and degradation. This review focuses on microglial membrane receptors that bind Aβ and contribute to microglial activation and/or Aβ phagocytosis and clearance. These receptors can be categorized into several groups. The scavenger receptors (SRs) include scavenger receptor A-1 (SCARA-1), MARCO, scavenger receptor B-1 (SCARB-1), CD36 and the receptor for advanced glycation end product (RAGE). The G protein-coupled receptors (GPCRs) are formyl peptide receptor 2 (FPR2) and chemokine-like receptor 1 (CMKLR1). There are also toll-like receptors (TLRs) including TLR2, TLR4, and the co-receptor CD14. Functionally, SCARA-1 and CMKLR1 are involved in the uptake of Aβ, and RAGE is responsible for the activation of microglia and production of proinflammatory mediators following Aβ binding. CD36, CD36/CD47/α6β1-intergrin, CD14/TLR2/TLR4, and FPR2 display both functions. Additionally, MARCO and SCARB-1 also exhibit the ability to bind Aβ and may be involved in the progression of AD. Here, we focus on the expression and distribution of these receptors in microglia and their roles in microglia interaction with Aβ. Finally, we discuss the potential therapeutic value of these receptors in AD.
Insights
Microglial membrane receptors bind amyloid-beta (Aβ), influencing Alzheimer's disease (AD) progression. Targeting these receptors offers potential therapeutic strategies for AD by modulating microglial activation and Aβ clearance.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Amyloid-beta (Aβ) aggregation and neuroinflammation are key drivers of Alzheimer's disease (AD).
- Microglia, the brain's immune cells, interact with Aβ through various membrane receptors, influencing both disease activation and clearance.
- Understanding these microglial-Aβ interactions is crucial for developing effective AD therapies.
Purpose of the Study:
- To review microglial membrane receptors that bind Aβ.
- To categorize these receptors and elucidate their roles in microglial activation, Aβ phagocytosis, and clearance.
- To discuss the therapeutic potential of targeting these receptors in AD.
Main Methods:
- Literature review focusing on microglial membrane receptors involved in Aβ binding.
- Categorization of receptors including scavenger receptors (SRs), G protein-coupled receptors (GPCRs), and Toll-like receptors (TLRs).
- Analysis of receptor functions in Aβ uptake, microglial activation, and inflammatory mediator production.
Main Results:
- Identified key receptors: SCARA-1, MARCO, SCARB-1, CD36, RAGE, FPR2, CMKLR1, TLR2, TLR4, and CD14.
- Demonstrated varied roles: SCARA-1 and CMKLR1 primarily mediate Aβ uptake; RAGE drives Aβ-induced inflammation; CD36 and FPR2 exhibit dual functions.
- MARCO and SCARB-1 also bind Aβ, potentially contributing to AD progression.
Conclusions:
- Microglial membrane receptors are critical mediators of Aβ interaction, impacting AD pathogenesis.
- Specific receptors like SCARA-1, RAGE, CD36, and FPR2 present distinct therapeutic targets.
- Targeting these receptors offers a promising avenue for novel Alzheimer's disease treatments.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22Alzheimer's Disease: Treatment